By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen was founded in 1980 under the name of AMGen (Applied Molecular Genetics) and quickly became a pioneer in biotechnology by creating protein drugs from human genes recombined in bacteria or cell cultures. Amgen was the first to develop two recombinant proteins: erythropoietin (EPOGEN®) and filgrastim G-CSF (NEUPOGEN®).
Now, Amgen is expanding its research fields and developing new generations of biotherapies. In the last decade, the company has demonstrated its innovative potential by delivering several fully human monoclonal antibodies for the treatment of metastatic colorectal cancer, chronic kidney disease, and osteoporosis.
